A landmark study published in The Lancet Regional Health – Europe demonstrates that multi-cancer early detection (MCED) tests using circulating cell-free DNA could identify one in five cancers that escape conventional diagnostic pathways in symptomatic patients.
The SYMPLIFY study’s retrospective analysis revealed an eight-fold difference in cancer diagnosis rates between patient groups, with those showing ‘false positive’ MCED results diagnosed at 7.9% compared to 1.0% in true negative cases. This striking disparity suggests that many reportedly false results may actually represent early cancer detection missed by standard approaches.
Researchers emphasize that MCED technology, capable of detecting signals across more than 50 cancer types, holds promise as a complementary clinical decision support tool alongside existing diagnostic methods rather than as a replacement.
Was this article helpful?
